If you're a medical device founder researching consulting firms for product strategy, you've probably hit the wall most founders hit: the firms with real depth (Boston Consulting Group's healthcare practice, ZS Associates, Putnam Associates, McKinsey & Company's MedTech practice) charge $50,000–$200,000 for engagements that produce decks. The boutique medical device consultancies are cheaper but often siloed — regulatory consultants who don't touch product, design firms who don't touch engineering, GTM consultants who don't speak FDA.
The gap most medical device founders are actually trying to fill is harder: a senior product leader who can be in the room when product, regulatory, clinical, engineering, and GTM trade-offs collide — for 18 months, not 6 weeks. That's a fractional CPO engagement. Here's why it works.
What Medical Device Product Strategy Actually Requires
Medical device product strategy is not a deliverable. It's a continuous sequence of trade-offs across four domains:
Regulatory pathway selection and protection. Are we 510(k), De Novo, or breakthrough? Are we Class I, II, or III? Are we a software accessory to a hardware device, a SaMD, or a clinical decision support tool exempt under the 2016 Cures Act? Each path has different timeline, cost, and post-market obligation profiles. Picking the wrong path early can add 18 months and millions of dollars; picking the right path requires understanding both the FDA framework and the actual product. A fractional CPO doesn't replace the regulatory consultant — they make sure product decisions don't accidentally close off a faster pathway.
Clinical workflow integration. Most medical device features die during clinical implementation, not engineering. A workflow that adds 30 seconds to an 8-minute visit fails at scale. A decision-support feature that fires too often creates alarm fatigue. The fractional CPO is part of the clinical advisory process, structures the user research, and translates clinician feedback into roadmap decisions that engineering can execute.
Build-vs-buy calls on regulated infrastructure. Quality Management System (QMS) software (Greenlight Guru, MasterControl, Veeva), e-QMS for design controls, electronic data capture (EDC) for clinical evidence collection, post-market surveillance tooling — every infrastructure layer in a medical device company has both an enterprise-grade vendor option and a build-it-ourselves option. Build the wrong things and you spend 12 months on undifferentiated infrastructure; buy the wrong things and you're locked into licensing and vendor risk for the life of the product. These calls require both regulatory understanding and product judgment.
Reimbursement and payer strategy. Medical device commercial success increasingly depends on CPT/HCPCS code strategy, prior authorization workflows, and payer relationship management. Product decisions made without a payer model in mind can produce a clinically excellent device that no insurer will reimburse. The fractional CPO sits between the regulatory team, the commercial team, and the engineering team to make sure these don't drift apart.
A six-week consulting engagement can produce a deck describing the framework for these decisions. It cannot make them. Decisions made by a fractional CPO embedded in the team for 12–24 months are different in kind from decisions documented by a consultant.
Where Big Consulting Firms Add Real Value (And Where They Don't)
Honest take, because medical device founders deserve it:
Big consulting firms add real value for: market sizing studies for board presentations, competitive landscape analyses for fundraising, payer strategy assessments for major commercial pivots, post-acquisition strategic assessments, and benchmarking studies that compare your operational metrics against industry norms. These are well-defined deliverables where the firm's data assets and analyst leverage actually matter.
Big consulting firms struggle with: ongoing product decisions where the right answer changes weekly, integration with engineering and design where the firm doesn't have the team, GTM execution that requires sitting in customer conversations, post-clearance product evolution where the strategy needs to evolve with real-world data, and any work where the deliverable is a shipped product rather than a slide deck.
A fractional CPO is the inverse: poor fit for one-time market studies (the $14K/month is overkill for a $40K market sizing project), great fit for the ongoing product, GTM, and team-leadership work where embedded judgment compounds.
The right answer for many medical device founders is to use both — a focused big-firm engagement for a specific market study or commercial pivot assessment, plus a fractional CPO for the ongoing product strategy and team leadership.
What a Medical Device Fractional CPO Engagement Looks Like
Our typical medical device CPO engagement spans 12–24 months and runs at the Fractional ($14K/month, 2 days/week) or Embedded ($20K/month, 3+ days/week) tier. The first 90 days set the foundation:
Weeks 1–2: Product audit. Roadmap review, clinical advisory feedback synthesis, regulatory pathway alignment, GTM and reimbursement assessment, product-team capability review. Output: written report ranked by business impact, not just product-team wishlist.
Week 3–4: 90-day plan workshop. Three measurable product outcomes for the quarter, sequenced workstreams, research priorities, team and tool requirements, success metrics. Sign-off from CEO and clinical advisory before retainer kicks in.
Weeks 5–12: Embedded execution. Roadmap ownership, customer and clinician research, product-engineering coordination, regulatory submission prep coordination (with the regulatory consultant), GTM and pricing decisions, board prep on product progress.
Months 4–24: Sustained engagement. Roadmap evolution as clinical data emerges, post-clearance product strategy, second-product line decisions, M&A diligence support if relevant, hiring of the eventual full-time CPO when the company is ready.
We've shipped products through this engagement model across digital health, medical device, and clinical workflow tools — including scaling Aesthetic Record's EMR platform to 4,000+ US clinics and supporting A'alda's veterinary healthcare platform from founding through Tokyo IPO. Our fractional CPO services explain the standard engagement structure in more detail.
The Cost Comparison
For founders comparing options:
| Option | Typical cost | Time to deliverable | What you get |
|---|---|---|---|
| Big consulting firm engagement | $50K–$200K | 6–12 weeks | Strategy deck, framework, recommendations |
| Boutique medical device consultancy | $20K–$60K | 4–10 weeks | Focused-domain deliverable (regulatory, clinical, GTM) |
| Full-time CPO (with healthcare/MedTech experience) | $400K–$550K all-in | 9–12 month search + 3–6 month ramp | Full executive in seat |
| Fractional CPO (Embedded tier) | $20K/month × 12–24 months = $240K–$480K | 2 weeks to embed, 12–24 months engagement | Embedded executive making decisions weekly |
How to Decide
A fractional CPO is the right shape if:
- You have product complexity that needs ongoing judgment, not a one-time deliverable
- You're 12–24 months from a Series B raise where investor diligence on product strategy will be intense
- You have a clinical advisor and a regulatory advisor but the connective tissue between them and engineering is missing
- Your full-time CPO search is in flight (or hasn't started) and you need leadership now
- You have a defined deliverable (market study, payer strategy, M&A diligence) with clear scope
- You need data assets the firm has (sizing models, competitor benchmarks, payer claims data)
- The engagement informs a single major decision rather than ongoing product work
- Your board specifically wants a name-brand firm's logo on the deck
Need help thinking this through?
If you're weighing how to structure product leadership for a medical device company, book a 30-min call — no pitch. We'll give you three specific recommendations regardless of whether we end up working together. Book a Free 30-Min Strategy Call →